COPD death rates: projecting a female trajectory
- Inhaled corticosteroids and COPD exacerbations. Kuritzky, Louis // Clinical Oncology Alert;Apr2010 Supplement 2, p8
The article discusses research on the effectiveness of inhaled corticosteroids (ICS) in preventing chronic obstructive pulmonary disease (COPD) exacerbation, by R. Agarwal and colleagues, published in the 2010 issue of "Chest."
- Chronic Corticosteroid Use in Patients with COPD. Nuovo, Jim // American Family Physician;01/15/2001, Vol. 63 Issue 2, p364
Presents an abstract of the study `Withdrawal of Chronic Systemic Corticosteroids in Patients With COPD: A Randomized Trial,' by K.L. Rice et al., from the July 2000 issue of the `American Journal of Respiratory and Critical Care Medicine.'
- Do Oral Corticosteroids Help Exacerbations of COPD? Walling, Anne D. // American Family Physician;11/15/1999, Vol. 60 Issue 8, p2415
Presents an abstract of the study `Oral Corticosteroids in Patients Admitted to Hospital With Exacerbations of Chronic Obstructive Pulmonary Disease: A Prospective Randomised Controlled Trial,' by L. Davis et al., which appeared on the August 7, 1999 issue of `The Lancet.'
- Five days of corticosteroid for exacerbations of COPD. // BMJ: British Medical Journal;6/1/2013, Vol. 346 Issue 7910, p11
The article reports that five days of oral prednisolone are sufficient for most people with an acute exacerbation of chronic obstructive pulmonary disease (COPD) and states that it works well against corticosteroid and limit exposure and side effects of drugs.
- Triple therapy for COPD demonstrates benefit, fails to meet end point in randomized study. // Formulary;May2007, Vol. 42 Issue 5, p308
The article presents a study demonstrating benefits of triple therapy with tiotropium plus salmeterol (SAL) and fluticasone for patients with chronic obstructive pulmonary disease (COPD). Numerous data revealed that the triple therapy failed to reduce the proportion of patients with COPD...
- Inhaled corticosteroid therapy for patients with persistent asthma: Learnings from studies of inhaled budesonide. Chipps, Bradley E. // Allergy & Asthma Proceedings;May/Jun2009, Vol. 30 Issue 3, p217
Inhaled corticosteroids (ICSs) are recommended for patients with asthma who use a short-acting Î²2-adrenergic agonist more than twice weeklyâ€”a key indicator of disease persistency. Much knowledge about the long-term benefits of ICSs in persistent asthma stems from studies of the ICS...
- LABA/ICS Fixed-Dose Combinations Are the Most Commonly Prescribed Maintenance Therapies for Newly Diagnosed COPD Patients. // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1
The article focuses on the research analysis titled "Treatment Algorithms in Chronic Obstructive Pulmonary Disease," from BioTrends Research Group LLC. The research finds that finds that long-acting beta2 agonist (LABA) and inhaled corticosteroid (ICS) fixed-dose combinations are the most...
- Benefits and Risks of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. Bonay, M.; Bancal, C.; Crestani, B. // Drug Safety;2002, Vol. 25 Issue 1, p57
Inhaled corticosteroids have a proven benefit in the management of asthma, but until recently, their efficacy in non-asthmatic, smoking-related chronic obstructive pulmonary disease (COPD) was not evidence-based. Airway inflammation in COPD differs from inflammation in asthma. Some studies have...
- Inhaled corticosteroids and COPD exacerbations. Kuritzky, Louis // Internal Medicine Alert;3/29/2010, Vol. 32 Issue 6, p48
The article reports on the effectiveness of inhaled corticosteroids (ICS) in treating acute exacerbations of chronic obstructive pulmonary disease (AC-COPD).